Nektar presents long-term data on alopecia areata drug candidate

Nektar Therapeutics has unveiled long-term data from extended studies on its drug candidate, rezpegaldesleukin, for the treatment of alopecia areata and atopic dermatitis. The Phase 2b REZOLVE-AA study, which included 31 alopecia areata patients, demonstrated that 75% maintained a SALT Score of 20 or below four months after stopping treatment, with 63% retaining this response at six months off treatment.

The study also showed a gradual increase in the proportion of patients achieving a SALT Score of 10 or below, from 7% at week 52 to 19% after six months off treatment. Nektar has initiated a third Phase 3 study in atopic dermatitis for treatment-experienced patients and a Phase 3 study in alopecia areata, called ZENITH AA, set to begin in early 2027 with 850 patients.

The company has received FDA Fast Track designation for rezpegaldesleukin in atopic dermatitis and severe alopecia areata.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.